Document is current
Any future updates will be listed below
-
Authors
Hayashi, Hikaru
Seki, Sayaka
Tomita, Takeshi https://orcid.org/0000-0001-6815-2244
Kato, Masayoshi https://orcid.org/0000-0003-2170-3373
Ashihara, Norihiro https://orcid.org/0000-0003-0158-7133
Chano, Tokuhiro https://orcid.org/0000-0002-9959-1183
Sanjo, Hideki
Kawade, Miwa
Yan, Chenhui
Sakai, Hiroki
Tomida, Hidenori
Tanaka, Miyuki
Iwaya, Mai
Taki, Shinsuke https://orcid.org/0000-0001-5143-3496
Nakazawa, Yozo
Soejima, Yuji
Ueno, Yoshihito
Hiratsuka, Sachie https://orcid.org/0000-0002-6507-7362
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (22H02900)
- License Information
-
More Information
Article History
Received: 2 May 2024
Accepted: 11 February 2025
First Online: 25 February 2025
Competing interests
: T. Chano is the president and CEO of GF Mille Co. Ltd. M. Kawade served as a member of GF Mille Co. Ltd. Y. Ueno is a senior advisor of GF Mille Co. Ltd. S. Hiratsuka has received research funding from GF Mille Co. Ltd. and Bourbon Corp., and a manuscript fee from Nippon Boehringer Ingelheim Co. Ltd. Y. Soejima reports grant to his institution from Kaken Pharmaceutical Co. Ltd. and has received fees from Eli Lilly Japan K.K., AstraZeneca K.K., Eisai Co. Ltd., Miyarisan Pharmaceutical Co. Ltd., Merck & Co. Inc., TAIHO Pharmaceutical Co. Ltd., Novartis Pharma K.K., Takeda Pharmaceutical Co. Ltd., EA Pharma Co. Ltd., Chugai Pharmaceutical Co. Ltd., TEIJIN Pharma Ltd., TSUMURA Co. Ltd., Otsuka Pharmaceutical Factory Inc., Guardant Health Japan Corp., and ONO Pharmaceutical Co. Ltd. Y. Nakazawa and M. Tanaka are shareholders of A-SEEDS Co. Ltd. Y Nakazawa reports grants to his institution from A-SEEDS Co. Ltd., BrightPath Biotherapeutics Co. Ltd., AGC Inc., Toshiba Corp., Daiichi Sankyo Co. Ltd., Bourbon Corp., Cell Science & Technology Institute, Inc., and Sekisui Chemical Co. Ltd, and has received fees from Bourbon Corp., Novartis Pharma K.K., Ajinomoto Co. Inc., Daiichi Sankyo Co. Ltd., and AstraZeneca K.K. All other authors report no competing interests.
